Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26167758 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Fedor Moiseenko und 24 weiteren Autor:innen. Beteiligte Einrichtung: St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) Named After N.P. Napalkov, Leningradskaya…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian state-funded project for ICBFM SB RAS, Russian Science Foundation.
Abstract (Originalsprache)
The efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) varies widely across patients. Growing evidence indicates that the gut microbiome, through its interaction with the tumor microenvironment, may influence the response to immunotherapy. To investigate this, we analyzed fecal and tumor samples from 63 patients with inoperable NSCLC undergoing ICI therapy. Based on microbiome profiling using 16S rRNA sequencing, patients were grouped according to treatment benefit, defined as progression-free survival (PFS) of six months or longer. Associations between α-diversity indices, microbial composition at the genus and phylum levels, and a composite Sum Index of Binary Abundance (SIBA) were examined in relation to clinical outcomes. Higher microbial α-diversity was linked to improved response to ICIs (p-value = 0.0078 for the Chao1 index). Multiple specific taxa, such as Ruminococcus gauvreauii (p-value = 2 × 10−4), Ruminiclostridium 9 (p-value = 8 × 10−4), and [Eubacterium] ventriosum (p-value = 9 × 10−4), were enriched in patients with favorable outcomes, whereas Oscillibacter and the Eubacterium hallii group were associated with disease progression (p-value = 2 × 10−3 and 9 × 10−3, respectively). The SIBA index, which reflects the absence of multiple beneficial bacterial taxa, proved to be a stronger predictor of treatment response than individual taxa alone. Median SIBA values were 18 vs. 24 in patients benefiting from IO therapy compared to non-responders (p-value = 9 × 10−7). These findings suggest that gut microbiome diversity and composition are closely tied to immunotherapy outcomes in NSCLC. Composite microbial metrics like SIBA may enhance predictive accuracy and inform personalized treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) Named After N.P. Napalkov, Leningradskaya Str. 68A, Litera A, 197758 St. Petersburg, Russia.
- N.N. Petrov National Medical Research Center of Oncology, Ministry of Public Health of the Russian Federation, Leningradskaya Str. 68, 197758 St. Petersburg, Russia.
- Faculty of Oncology, North-Western State Medical University Named After I.I. Mechnikov, Kirochnaya Str. 41, 191015 St. Petersburg, Russia.
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 8 Lavrentiev Avenue, 630090 Novosibirsk, Russia.
- Department of Medical Genetics and Oncology, Pediatric Oncology, and Radiation Therapy, Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State Pediatric Medical University" of the Mi…
- Federal State-Financed Institution Pediatric Research and Clinical Center for Infectious Diseases, the Federal Medical Biological Agency, Professor Popov Str. 9, 197022 St. Petersburg, Russia.
ORCID-Profile: Fedor Moiseenko, Andrey Kechin, Maksim Koryukov, Ulyana Boyarskikh, Ekaterina Kuligina, Aglaya Iyevleva, Sergey Sidorenko, Vladimir Gostev, Alexey Komissarov
Förderung
- Russian state-funded project for ICBFM SB RAS
- Russian Science Foundation
Zitieren
APA
Moiseenko, F., Kechin, A., Koryukov, M., Boyarskikh, U., Gabina, A., Oganesian, A., Belukhin, S., Makarkina, M., Elsakova, E., Artemeva, E., Myslik, A., Volkov, N., Bogdanov, A., Kuligina, E., Aleksakhina, S., Iyevleva, A., Ivantsov, A., Bogdanov, A., Sidorenko, S., …, & Moiseyenko, V. (2025). Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167758
Vancouver
Moiseenko F, Kechin A, Koryukov M, Boyarskikh U, Gabina A, Oganesian A, et al. Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167758
BibTeX
@article{Moiseenko2025,
author = {Moiseenko, Fedor and Kechin, Andrey and Koryukov, Maksim and Boyarskikh, Ulyana and Gabina, Albina and Oganesian, Ani and Belukhin, Sergey and Makarkina, Maria and Elsakova, Ekaterina and Artemeva, Elizaveta and Myslik, Alexander and Volkov, Nikita and Bogdanov, Alexey and Kuligina, Ekaterina and Aleksakhina, Svetlana and Iyevleva, Aglaya and Ivantsov, Alexander and Bogdanov, Andrey and Sidorenko, Sergey and Gostev, Vladimir and Komissarov, Alexey and Dudurich, Vasilisa and Danilov, Lavrenty and Imyanitov, Evgeny and Moiseyenko, Vladimir},
title = {Interconnection of Gut Microbiome and Efficacy of Immune Checkpoint Inhibitors in Inoperable Non-Small-Cell Lung Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26167758}
}
EUVIMED